ArriVent BioPharma, Inc. AVBP Operating Lease Liabilities (Current)
Operating Lease Liabilities (Current) at other companies
Other financials
Where this comes from
Reported directly by ArriVent BioPharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.
The official record: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about ArriVent BioPharma, Inc.'s operating lease liabilities (current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ArriVent BioPharma, Inc.'s operating lease liabilities (current)?
- ArriVent BioPharma, Inc. (AVBP) reported operating lease liabilities (current) of $99K in Q1 2026.
- How has ArriVent BioPharma, Inc.'s operating lease liabilities (current) changed year-over-year?
- ArriVent BioPharma, Inc.'s operating lease liabilities (current) decreased by 28.3% year-over-year, from $138K to $99K.
- What is the long-term trend for ArriVent BioPharma, Inc.'s operating lease liabilities (current)?
- Over 2 years (2023 to 2025), ArriVent BioPharma, Inc.'s operating lease liabilities (current) has grown at a -68.4% compound annual growth rate (CAGR), from $140K to $14K.
- What does operating lease liabilities (current) mean?
- The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.